HTA Method Shifts & Pricing Trends

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics are particularly timely as we're seeing fundamental shifts in how value is assessed globally.

MarcusSame here. We're looking at NICE's threshold consultation implications — which could redefine cost-effectiveness benchmarks. Then EMA's rare disease adaptive pathway expansion — signaling a major shift in evidence generation models. And CMS Part D redesign operational hurdles — highlighting real-world implementation challenges in US pricing policy.

SaraThat second one is interesting to me — the adaptive pathway expansion raises critical questions about long-term data requirements and how payers will interpret interim evidence.

MarcusExactly. Let's get into it.

MarcusStarting with NICE's threshold consultation. The signals suggest they're reconsidering the £20,000-30,000 per QALY range for highly specialized technologies. What's striking here is the explicit acknowledgment that traditional thresholds may not capture the full value of transformative therapies, especially in rare diseases.

SaraI'd push back slightly on that — the consultation focuses on the £50,000 threshold for ultra-orphan drugs, but the real tension is whether this creates a two-tiered system. Payers will need to justify why some therapies get special consideration while others don't, and that could lead to inconsistent decision-making.

MarcusThat's fair, though I think NICE is trying to address the innovation paradox where truly novel therapies often have higher development costs but limited comparators. The question is whether a higher threshold alone solves that or if it requires complementary adjustments to their decision framework.

SaraThe part that gives me pause is the budget impact implications. If we move toward higher thresholds for select therapies, it doesn't address the underlying system sustainability concerns. We might need more sophisticated value assessment models that incorporate broader societal benefits beyond pure cost-effectiveness.

MarcusThat connects to something I keep coming back to — the consultation's emphasis on equity considerations alongside economic metrics. NICE is explicitly asking how thresholds should account for health inequalities, which could fundamentally alter their value proposition.

SaraRight, and from the payer side, that operationalizes into very real coverage decisions. If equity becomes a formal criterion, how do we measure it objectively? This could create significant variability in how different health systems interpret the same evidence.

MarcusExactly. The consultation closes next month, and we'll be watching how industry responds with evidence that bridges this gap between innovation and system constraints.

SaraShifting to EMA's rare disease adaptive pathway expansion. This isn't just a procedural update; it represents a structural shift in how regulators approach evidence generation for ultra-rare conditions. What strikes me is the explicit integration of post-authorization data requirements from the outset.

MarcusI wonder if that's the full picture though. The pathway allows for smaller initial trials with longer follow-up, but the real challenge will be ensuring that real-world evidence collected post-approval aligns with regulatory expectations. We've seen historically that RWE acceptance often lags behind regulatory innovation.

SaraThat's one read — I'd frame it slightly differently. The expansion specifically mentions adaptive licensing elements like rolling reviews and conditional approvals, which could accelerate patient access. But the methodological guardrails around RWE integration remain underdeveloped, and that could create access delays later.

MarcusThe part that gives me pause is how this interacts with HTA bodies. If EMA approves via adaptive pathways but HTA requires more mature data, we risk creating transatlantic divergence. The pathway mentions collaboration with HTA agencies, but the operational details are still vague.

SaraWhat strikes me about that is the precedent it sets for gene therapies. If rare diseases become the test case for adaptive pathways, we need to watch how this scales to more common conditions with similar evidence challenges. The methodology developed here could reshape the entire HTA landscape.

MarcusThat's fair. The expansion specifically includes provisions for patient involvement in trial design, which could address some of the historical gaps in patient-reported outcomes. But the real test will be whether these pathways genuinely reduce development time without compromising evidence quality.

SaraAgreed. We'll be watching the first adaptive pathway approvals to see how payers respond to these novel evidence packages.

SaraNow, CMS Part D redesign operational hurdles. The implementation challenges are becoming clearer — particularly around the negotiation process and formulary design. What's concerning is the disconnect between policy intent and operational reality.

MarcusI'd frame it slightly differently. The hurdles aren't just procedural; they reflect fundamental tensions in the system. The negotiation timeline is tight, and we're seeing significant pushback from manufacturers on the evidence requirements. The question is whether CMS can maintain its aggressive schedule while ensuring fair process.

SaraThat's one read — but what strikes me is the budget impact miscalculation. The original savings projections assumed rapid uptake of negotiated prices, but the operational delays mean savings won't materialize as quickly. This creates a funding gap that could impact other Part D initiatives.

MarcusThe part that gives me pause is how this interacts with the inflation rebates. If negotiations are delayed, the rebate program's financial impact gets compressed into shorter periods, potentially destabilizing plan budgets. We're already seeing some PBMs requesting adjustments to the payment schedule.

SaraRight, and from the payer side, this creates uncertainty in formulary planning. If they can't predict when drugs will be available at negotiated prices, it complicates coverage decisions. The operational complexity is undermining the policy's goal of predictable pricing.

MarcusExactly. The CMS has acknowledged these challenges but hasn't signaled any timeline adjustments. We'll be watching whether they extend the negotiation window or modify the implementation phases.

MarcusFinally, FDA decentralized trials guidance impact. This draft guidance isn't just about trial design; it represents a fundamental shift in how we generate evidence for rare and geographically dispersed populations. What's striking is the explicit acceptance of digital endpoints and virtual assessments.

SaraI wonder if that's the full picture though. While the guidance expands flexibility, it creates new methodological challenges around data standardization and endpoint validation. Payers will need reassurance that decentralized trial data meets the same evidentiary standards as traditional trials.

MarcusThat's fair, though I think the FDA is responding to real-world constraints. The guidance specifically addresses the feasibility challenges for ultra-rare diseases where traditional trial designs are impractical. The question is whether this accelerates development or creates new evidence interpretation hurdles.

SaraWhat strikes me about that is the global implications. If the FDA leads with decentralized trials, we may see divergence in how other regulators view this evidence. The guidance mentions international collaboration, but the operational harmonization is still nascent.

MarcusThe part that gives me pause is the patient burden aspect. While decentralized trials reduce travel burdens, they increase the cognitive load on participants to use digital tools. This could introduce selection bias that affects generalizability. The guidance acknowledges this but doesn't provide clear mitigation strategies.

SaraThat's one read — I'd frame it slightly differently. The real opportunity is in generating more representative evidence by including traditionally underrepresented populations. But the operational challenges around digital literacy and access could widen existing disparities if not addressed proactively.

MarcusExactly. The comment period closes next month, and we'll be watching how industry responds with evidence that demonstrates both the feasibility and reliability of these novel approaches.

SaraA lot to think about today. I'll be watching how NICE's threshold consultation evolves and whether it sets a precedent for other health systems. The adaptive pathway expansion also signals a major shift in evidence generation that could redefine rare disease access globally.

MarcusSame — and for me the thread running through today is the growing tension between regulatory innovation and HTA methodology. As agencies adapt to scientific advances, the operational challenges are becoming the real barriers to access. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.